Skip to main content
. Author manuscript; available in PMC: 2019 May 13.
Published in final edited form as: J Clin Virol. 2015 Jun 19;69:172–175. doi: 10.1016/j.jcv.2015.06.086

Figure 2.

Figure 2

Commercial IVIG lots neutralize EV-D68 strains with equivalent efficiencies. IVIG products were tested for neutralizing antibodies against the EV-D68 strains Fermon (A) and three clinical isolates 14–18949 (B), 14–18952 (C), and 14–18953 (D). For each manufacturer, median neutralization titers are indicated in box plots with horizontal line with 5–95% confidence intervals. (A, n=10; B, n=10; C, n=3; D, n=4, E, n=2). Data represents results from a single assay run. *p < 0.05, ** p < 0.01, *** p < 0.001 for difference in median titers.